vs
EGAIN Corp（EGAN）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
EGAIN Corp的季度营收约是STANDARD BIOTOOLS INC.的1.2倍（$23.0M vs $19.6M），EGAIN Corp净利率更高（10.2% vs -177.4%，领先187.6%），EGAIN Corp同比增速更快（2.6% vs -11.5%），EGAIN Corp自由现金流更多（$9.9M vs $-23.1M），过去两年EGAIN Corp的营收复合增速更高（1.4% vs -12.2%）
eGain公司总部位于加利福尼亚州桑尼维尔，主营人工智能知识软件开发，助力企业实现客户体验与员工工作流程的智能化自动化升级，帮助企业提升运营效率，优化服务质量。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
EGAN vs LAB — 直观对比
营收规模更大
EGAN
是对方的1.2倍
$19.6M
营收增速更快
EGAN
高出14.1%
-11.5%
净利率更高
EGAN
高出187.6%
-177.4%
自由现金流更多
EGAN
多$33.0M
$-23.1M
两年增速更快
EGAN
近两年复合增速
-12.2%
损益表 — Q2 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $19.6M |
| 净利润 | $2.3M | $-34.7M |
| 毛利率 | 73.1% | 48.5% |
| 营业利润率 | 8.9% | -168.5% |
| 净利率 | 10.2% | -177.4% |
| 营收同比 | 2.6% | -11.5% |
| 净利润同比 | 248.1% | -28.8% |
| 每股收益（稀释后） | $0.08 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EGANLAB
| Q4 25 | $23.0M | — | ||
| Q3 25 | $23.5M | $19.6M | ||
| Q2 25 | $23.2M | $21.8M | ||
| Q1 25 | $21.0M | $40.8M | ||
| Q4 24 | $22.4M | — | ||
| Q3 24 | $21.8M | $22.1M | ||
| Q2 24 | $22.5M | $22.5M | ||
| Q1 24 | $22.4M | $45.5M |
净利润EGANLAB
| Q4 25 | $2.3M | — | ||
| Q3 25 | $2.8M | $-34.7M | ||
| Q2 25 | $30.9M | $-33.5M | ||
| Q1 25 | $66.0K | $-26.0M | ||
| Q4 24 | $671.0K | — | ||
| Q3 24 | $652.0K | $-26.9M | ||
| Q2 24 | $1.5M | $-45.7M | ||
| Q1 24 | $1.5M | $-32.2M |
毛利率EGANLAB
| Q4 25 | 73.1% | — | ||
| Q3 25 | 75.2% | 48.5% | ||
| Q2 25 | 72.7% | 48.8% | ||
| Q1 25 | 68.0% | 48.4% | ||
| Q4 24 | 70.2% | — | ||
| Q3 24 | 69.4% | 54.9% | ||
| Q2 24 | 69.3% | 46.1% | ||
| Q1 24 | 69.3% | 53.1% |
营业利润率EGANLAB
| Q4 25 | 8.9% | — | ||
| Q3 25 | 12.1% | -168.5% | ||
| Q2 25 | 14.0% | -118.1% | ||
| Q1 25 | 0.1% | -80.8% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 2.3% | -120.9% | ||
| Q2 24 | 5.3% | -134.5% | ||
| Q1 24 | 4.2% | -132.2% |
净利率EGANLAB
| Q4 25 | 10.2% | — | ||
| Q3 25 | 12.0% | -177.4% | ||
| Q2 25 | 132.8% | -153.7% | ||
| Q1 25 | 0.3% | -63.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 3.0% | -122.0% | ||
| Q2 24 | 6.7% | -203.3% | ||
| Q1 24 | 6.7% | -70.6% |
每股收益（稀释后）EGANLAB
| Q4 25 | $0.08 | — | ||
| Q3 25 | $0.10 | $-0.09 | ||
| Q2 25 | $1.09 | $-0.09 | ||
| Q1 25 | $0.00 | $-0.07 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.02 | $-0.07 | ||
| Q2 24 | $0.05 | $-0.12 | ||
| Q1 24 | $0.05 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $83.1M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $88.8M | $399.7M |
| 总资产 | $146.8M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EGANLAB
| Q4 25 | $83.1M | — | ||
| Q3 25 | $70.9M | $129.4M | ||
| Q2 25 | $62.9M | $158.6M | ||
| Q1 25 | $68.7M | $150.9M | ||
| Q4 24 | $70.5M | — | ||
| Q3 24 | $67.2M | $210.6M | ||
| Q2 24 | $70.0M | $269.8M | ||
| Q1 24 | $83.0M | $287.1M |
总债务EGANLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益EGANLAB
| Q4 25 | $88.8M | — | ||
| Q3 25 | $83.5M | $399.7M | ||
| Q2 25 | $80.7M | $424.5M | ||
| Q1 25 | $51.6M | $454.6M | ||
| Q4 24 | $55.3M | — | ||
| Q3 24 | $55.7M | $489.3M | ||
| Q2 24 | $58.5M | $510.3M | ||
| Q1 24 | $63.9M | $577.3M |
总资产EGANLAB
| Q4 25 | $146.8M | — | ||
| Q3 25 | $144.6M | $539.6M | ||
| Q2 25 | $148.0M | $557.0M | ||
| Q1 25 | $106.2M | $579.6M | ||
| Q4 24 | $111.3M | — | ||
| Q3 24 | $114.9M | $681.5M | ||
| Q2 24 | $127.9M | $708.7M | ||
| Q1 24 | $120.3M | $777.7M |
负债/权益比EGANLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.1M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $9.9M | $-23.1M |
| 自由现金流率自由现金流/营收 | 43.0% | -118.1% |
| 资本支出强度资本支出/营收 | 1.0% | 4.5% |
| 现金转化率经营现金流/净利润 | 4.33× | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流EGANLAB
| Q4 25 | $10.1M | — | ||
| Q3 25 | $10.4M | $-22.2M | ||
| Q2 25 | $-4.3M | $-20.7M | ||
| Q1 25 | $2.2M | $-30.3M | ||
| Q4 24 | $6.4M | — | ||
| Q3 24 | $954.0K | $-27.9M | ||
| Q2 24 | $-5.1M | $-39.0M | ||
| Q1 24 | $1.7M | $-62.5M |
自由现金流EGANLAB
| Q4 25 | $9.9M | — | ||
| Q3 25 | $10.2M | $-23.1M | ||
| Q2 25 | $-4.5M | $-22.6M | ||
| Q1 25 | $2.1M | $-35.3M | ||
| Q4 24 | $6.3M | — | ||
| Q3 24 | $845.0K | $-30.1M | ||
| Q2 24 | $-5.2M | $-41.0M | ||
| Q1 24 | $1.7M | $-63.3M |
自由现金流率EGANLAB
| Q4 25 | 43.0% | — | ||
| Q3 25 | 43.4% | -118.1% | ||
| Q2 25 | -19.5% | -103.6% | ||
| Q1 25 | 10.0% | -86.6% | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | 3.9% | -136.4% | ||
| Q2 24 | -23.0% | -182.2% | ||
| Q1 24 | 7.8% | -138.9% |
资本支出强度EGANLAB
| Q4 25 | 1.0% | — | ||
| Q3 25 | 1.0% | 4.5% | ||
| Q2 25 | 0.9% | 8.7% | ||
| Q1 25 | 0.5% | 12.4% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | 10.2% | ||
| Q2 24 | 0.2% | 8.6% | ||
| Q1 24 | 0.1% | 1.7% |
现金转化率EGANLAB
| Q4 25 | 4.33× | — | ||
| Q3 25 | 3.70× | — | ||
| Q2 25 | -0.14× | — | ||
| Q1 25 | 33.48× | — | ||
| Q4 24 | 9.57× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | -3.40× | — | ||
| Q1 24 | 1.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EGAN
| Transferred Over Time | $22.0M | 96% |
| Technology Service | $1.2M | 5% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
